Results 181 to 190 of about 2,385 (197)

Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor

JACC: Cardiovascular Interventions, 2017
Willibald Hochholzer, Michael Amann, Miroslaw Ferenc   +2 more
exaly  

Aspirin/cangrelor/ticagrelor

Reactions Weekly, 2022
openaire   +1 more source

Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist

Journal of Clinical Pharmacology, 2010
Julie H Oestreich, Steven R Steinhubl
exaly  

Cangrelor/ticagrelor interaction

Reactions Weekly, 2022
openaire   +1 more source

The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

Journal of Thrombosis and Haemostasis, 2008
J A Jakubowski, A Sugidachi, S Heptinstall   +2 more
exaly  

Cangrelor

2008
openaire   +1 more source

Cangrelor/heparin

Reactions Weekly, 2019
openaire   +1 more source

Aspirin/cangrelor/ticagrelor

Reactions Weekly, 2020
openaire   +1 more source

Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12receptorsin vitro

Platelets, 2016
Heather M Judge, Robert J Buckland, Robert F Storey   +2 more
exaly  

Aspirin/cangrelor

Reactions Weekly
openaire   +1 more source